Mereo BioPharma extends cooperation with Rubric Capital; Justin Roberts to remain on board through 2025 AGM

Mereo BioPharma Group plc

Extension letter dated April 15, 2024 waives resignation requirement for director Justin Roberts after 2024 AGM.
Termination date of Cooperation Agreement extended to immediately after the 2025 annual shareholder meeting.
Cooperation Agreement originally dated October 28, 2022 between Mereo and Rubric Capital Management L.P.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Mereo BioPharma Group plc entered into Extension Letter to Cooperation Agreement with Rubric Capital Management L.P. valued at Extension Letter waiving resignation requirement and extending termination date to after 2025 annual (effective 2024-04-15).

Action: entry
Counterparty: Rubric Capital Management L.P.
Value: Extension Letter waiving resignation requirement and extending termination date to after 2025 annual
Effective: 2024-04-15

Exact text from the filing

On April 15, 2024, Mereo BioPharma Group plc (the “Company”) entered into an extension letter, effective as of April 15, 2024 (the “Extension Letter”) to the cooperation agreement, dated October 28, 2022 (the “Cooperation Agreement”), between the Company and Rubric Capital Management L.P. (“Rubric Capital”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Mereo BioPharma Group plc filing history →

Source: SEC EDGAR

accession 0001193125-24-095508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.